CagriSema vs Foundayo: Should You Start Now or Wait?

CagriSema vs Foundayo is not a real two-drug choice yet. Foundayo is FDA-approved and available now — a daily pill with a current manufacturer self-pay price starting at $149 for a 30-day supply. CagriSema is still under FDA review in the United States. Novo Nordisk expects a U.S. decision in Q4 2026, but it has announced no approval, launch date, or price. So today, only one of them is something you can actually be prescribed.

Here's the part that changes the math, and almost nobody has written it down.

Yes, CagriSema produced roughly twice Foundayo's placebo-adjusted weight loss in two separate trials. That sounds like a great reason to wait. But the reason to wait quietly expired earlier this year — and it had nothing to do with Foundayo. Zepbound beat CagriSema in the one trial where the two were actually put side by side. Wegovy 7.2 mg also came close to CagriSema's separate-trial result, though that was not a direct comparison.

We'll show you exactly how, with the numbers, below.

Best for you / not for you

Foundayo is worth asking your doctor about if you:

• Want an FDA-approved medicine you can start now
• Really don't want needles
• Hate morning rules — you can take Foundayo with or without food, any time of day
• Want one of the lowest current manufacturer cash starting prices for an approved obesity GLP-1 — Foundayo and the Wegovy pill both start at $149
• Have Medicare Part D and may qualify for the temporary GLP-1 Bridge after prior authorization — eligible people pay a $50 copay
• Have kidney problems — the label requires no dose change, even for people on dialysis, though vomiting or diarrhea can still cause dehydration and kidney injury

Look somewhere else if you:

• Want the biggest average weight loss. That's Zepbound, and we'll say so plainly below
• Take birth control pills and don't want about six months of a backup method if you climb through every Foundayo dose at the fastest label pace
• Take carbamazepine or another strong CYP3A4 inducer, ritonavir or a similar drug that also blocks OATP1B, or more than 20 mg of simvastatin
• Have severe liver problems or severe gastroparesis
• Have you or a family member with medullary thyroid cancer, or you have MEN 2
• Are pregnant, trying to get pregnant, or breastfeeding
• Are waiting for CagriSema because you think it'll be in pharmacies in October. A Q4 decision window is not a pharmacy date

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

CagriSema vs Foundayo: the 10-second verdict

The one thing we'll admit before anything else

Foundayo did not produce the biggest average weight loss of the approved obesity GLP-1 medicines. In its main trial, the top dose produced 11.1% average weight loss when everyone randomized was counted. That is roughly half of what the strongest injections produced.

We're not going to dress that up.

It is not the smallest result in the whole class — Saxenda's main adult trial reported 7.4% — but Foundayo still sits well below Zepbound and high-dose Wegovy on average.

If the single biggest number is the only thing you care about, Foundayo is not your drug — and neither is CagriSema. Zepbound is. It's approved, it's in pharmacies, and in February 2026 it beat CagriSema in the one trial where the two were actually put side by side. If that's you, stop here and read Foundayo vs Zepbound instead. We'd rather lose you to the right page than keep you on the wrong one.

But here's what that number leaves out.

Foundayo isn't a peptide like semaglutide or tirzepatide. It's a small molecule — a completely different kind of chemistry. Peptide pills are hard to absorb, which is why the Wegovy pill makes you take it on an empty stomach with no more than four ounces of water and then wait 30 minutes before food, drinks, or other oral medicines. Foundayo skips all of that. One tablet. Any time. With food or without. No fasting, no timer, no fridge.

The best medicine on paper is worthless if you stop taking it. A drug you'll actually take at 11% can beat a drug you quit at 20%.

That's the trade. Now let's look at whether it's the right one for you.

See what Foundayo actually costs at each dose. Ro lists Foundayo at the same current cash prices Lilly publishes, dose by dose, before you commit to anything or talk to anyone. → See Foundayo's current price by dose on Ro (sponsored affiliate link) Medication and membership are billed separately. Prices verified August 8, 2026.

The right answer depends on you, not on the trial numbers

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

Is CagriSema FDA-approved, and can you get it yet?

No. As of August 8, 2026, CagriSema is not FDA-approved in the United States. Novo Nordisk filed its application with the FDA on December 18, 2025. In its August 2026 investor materials, the company said it still expects a U.S. decision in Q4 2026. It has not announced a launch date or a price, and approval is not guaranteed.

Read that last part again, because it's where most people get tripped up.

An FDA decision is not an approval. An approval is not a launch date. A launch date is not a pharmacy date. And a pharmacy date is not the date your insurance pays for it.

"Q4 2026" is a decision window, not a delivery date

Q4 means October through December. In that window, the FDA can approve the application, delay a decision, ask Novo for more information, or issue a complete response letter. Nobody outside the FDA knows what will happen.

And even approval would only be the first big gate.

The CagriSema availability ladder

This is the part that makes "should I wait?" answerable. There are eight steps between an application and a prescription you can actually fill. CagriSema has cleared the first, and the second is underway.

For comparison, Lilly moved Foundayo from FDA approval on April 1, 2026, to broad U.S. availability through LillyDirect, telehealth partners, and retail pharmacies on April 9 — about eight days. Lilly had prepared for launch before the decision. Whether Novo can move that fast is not public. Don't assume CagriSema shows up the week it is approved.

Can you buy CagriSema online right now?

No FDA-approved CagriSema is for sale today. And this one matters enough to be blunt.

The FDA has stated plainly that cagrilintide — one of CagriSema's two ingredients — cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition. There is no FDA-approved retail CagriSema path right now.

If a website is selling something called "CagriSema" or "cagrilintide" today, it is not FDA-approved CagriSema. "Research use only" on a label does not prove identity, strength, sterility, or safety for people.

Here's the argument we find most convincing, and it comes from Novo's own data. In CagriSema's main trial, doctors were allowed to keep patients on a lower dose when that worked better for them. Only 57.3% were on the top dose at week 68 — and the trial still hit its result. The dose ladder is the easy part to copy. The permission to come back down it is the part that doesn't come in a box.

Read more: CagriSema FDA approval status · What is CagriSema?

How much weight did CagriSema and Foundayo actually take off?

Counting everyone who was randomized, CagriSema produced 20.4% average weight loss over 68 weeks and Foundayo's top dose produced 11.1% over 72 weeks. By simple subtraction, CagriSema's result above placebo was about twice as large. These were two separate trials — the two drugs have never been tested against each other.

First, why every drug has two numbers

You'll see two different figures quoted for both of these drugs, and both can be honest. Here's the difference in plain terms.

Picture 100 people starting a medicine. Some stop the medicine, miss visits, or use another treatment.

• Number one estimates the result across everyone who was randomized, whether or not they stayed on treatment. This is the treatment-regimen or treatment-policy view.
• Number two estimates what might have happened if everyone had stayed on treatment and followed the trial plan. This is the efficacy view.

The second number was bigger for both drugs here. It is not a promise of what will happen to you, and it is not a fair reason to mix one drug's second number with another drug's first.

So we'll show you both, for both drugs.

Counting everyone who was randomized

The published CagriSema model reported a 17.3-point treatment difference; 17.4 is the simple subtraction of the two rounded group averages shown above.

If everyone had stayed on treatment

Our math: about double, whichever way you count

We did the division so you don't have to:

• Counting everyone: 17.4 ÷ 9.0 = 1.93×
• If everyone stayed on treatment: 20.4 ÷ 11.5 = 1.77×

Both come out between 1.8 and 1.9. When two different ways of counting agree, you can trust the shape of the answer. In separate trials, CagriSema produced roughly twice Foundayo's placebo-adjusted average weight loss.

We're not going to hide that or spin it. It's the honest read.

How much weight should you give this comparison?

Not all comparisons on this page are equally solid. Here's our grading, so you know where to lean hard and where to be careful.

Four things this comparison cannot control for: the two trials had different rules for raising doses, different people, different lengths, and different ways of handling participants who stopped treatment or had missing data. The gap between 20.4% and 11.1% is a gap between two separate averages. It is not a measured head-to-head result.

Why the dose numbers don't match: 36 mg on the paper, 17.2 mg on the bottle

Foundayo's early clinical trial papers use a capsule dose that topped out at 36 mg. The approved bottle tops out at a 17.2 mg tablet. Both are correct. The published ATTAIN-MAINTAIN paper maps all six investigational capsule doses to the six approved tablet doses. Here is the exact crosswalk.

This is the single most confusing thing about Foundayo, so we are clearing it up in one table.

If you've been reading about this drug, you've hit it. One article says people lost 12.4% on 36 mg. The next says the maximum dose is 17.2 mg. You reasonably conclude somebody's wrong.

Nobody's wrong. The formulation and dose numbers changed before approval.

So we built the table — and checked the three randomized maintenance doses against both ATTAIN-1 and ATTAIN-2.

How we know this is right

Three checks, all of which had to pass:

1. The published crosswalk is explicit. ATTAIN-MAINTAIN maps 1, 3, 6, 12, 24, and 36 mg capsules to 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg tablets in that order.
2. The obesity trial matches. All three randomized maintenance doses line up within a tenth of a percentage point.
3. The diabetes trial matches exactly. In ATTAIN-2, every row is identical — 5.1, 7.0, 9.6. Not close. The same.

Two trials, two journals, two different sets of patients, and the numbers land on top of each other. That's not a coincidence. It's the same data wearing different clothes.

Bonus: this is why you see both 11.1% and 11.2%

The FDA label rounds the marketed top-dose result to 11.1%. The New England Journal of Medicine paper reports 11.2% for the equivalent 36 mg capsule dose. Same trial result, two documents, one tenth of a point apart.

If you've been trying to work out which website got it wrong — neither number is wrong. Now you can read any Foundayo article and know instantly which dose language it's using.

Should you wait for CagriSema, or has that argument expired?

For most people, waiting no longer makes sense. The whole reason to wait was that CagriSema might be stronger than anything you could get. In 2026 that stopped being true: Zepbound produced more average weight loss than CagriSema in a direct 84-week trial, and the FDA approved Wegovy 7.2 mg with an 18.8% all-randomized label result in a separate 72-week trial.

This is the section we'd want a friend to read.

What's actually available right now

Every medicine in this table except CagriSema is FDA-approved and available in the United States today.

These rows put the main trials on the same broad ruler: the all-randomized or intent-to-treat result. They still are not head-to-head except where we say they are.

Look at the top three rows.

The waiting argument, in one paragraph

In 2025, waiting for CagriSema was a defensible plan. It isn't anymore, and two things killed it.

One. On February 23, 2026, Novo published the headline REDEFINE 4 result — CagriSema against tirzepatide, the ingredient in Zepbound, in the same trial and the same people. CagriSema produced 20.2% average weight loss under the treatment-regimen analysis. Tirzepatide produced 23.6%. Under the stay-on-treatment analysis, it was 23.0% versus 25.5%. CagriSema did not meet the trial's noninferiority goal.

Two. On March 19, 2026, the FDA approved Wegovy 7.2 mg. Its all-randomized label result was 18.8%, compared with CagriSema's 20.4% in a separate trial. That is not a tie, and it is not a direct comparison. But it is close enough to kill the idea that you must wait for CagriSema to get near that level of average weight loss. Wegovy 7.2 mg is not a starting dose: the label says it may be used when a patient has tolerated 2.4 mg for at least four weeks and more weight loss is clinically indicated.

So the trade you're weighing isn't "settle for less now, or get more later." It's "start an approved option now, or wait for an unapproved option that has already lost to an available drug in a direct trial."

What Novo says, and they deserve to be heard

Novo Nordisk has made a fair scientific point: adding the amylin ingredient cagrilintide produced more weight loss than semaglutide alone in the REDEFINE program. That is a genuine advance, and it may matter a great deal for some people. Novo is also studying other doses and longer treatment.

Novo Nordisk makes CagriSema and semaglutide.

Three good reasons to still wait

We're not going to pretend waiting is always wrong. It's a reasonable call if:

1. You're doing fine on what you're already taking. Don't fix what isn't broken.
2. You've already been through semaglutide and tirzepatide and neither did enough. CagriSema's second ingredient works on a different pathway from the obesity medicines approved today. That's a real reason to be curious.
3. You'd simply rather see the finished label and some real-world safety data before trying anything new. That's not timidity. That's caution, and it's fine.

Six bad reasons to wait

1. "The separate-trial number is bigger, so it'll work better for me." Trial averages aren't predictions about you.
2. "Q4 means I can pick it up in October." No. Q4 is a decision window. See the eight-gate ladder above.
3. "I'll stop what I'm on now so I'm ready." Please don't do this without your prescriber.
4. "I found something online that's close enough." It is not FDA-approved CagriSema, and federal law bars cagrilintide compounding.
5. "It'll probably be priced like Wegovy." Nobody knows. Novo hasn't announced a price.
6. "Insurance will cover it right away." No formulary coverage exists for a drug that has not been approved or launched.

The one real cost of waiting

Nobody likes being pushed, so we'll say this once and move on.

These medicines work while you take them. Six months of waiting isn't six months of missing out on a bigger number — Zepbound already beat CagriSema in a direct trial. It's six months of not starting an approved treatment that may fit you. That's the actual trade.

Still turning it over? Get a plan instead of another article. Tell us your state, your insurance situation, your budget, and whether you want a pill or a shot. Find My GLP-1 Path shows you the treatment paths that fit — with prices we've already verified. → Get your personalized GLP-1 plan Decided to wait on purpose? Good — that's a real choice. Track the CagriSema FDA decision so you can check the status without relying on rumors.

Which one is harder on your stomach?

CagriSema caused more nausea in its trial than Foundayo did in its trials — 55% versus 35% at Foundayo's top dose. But fewer people stopped CagriSema because of side effects: 5.9%, compared with 10% on Foundayo's top dose. Side effect rates from separate trials cannot be compared as though they came from one head-to-head study, and the backwards-looking gap has a plausible trial-design explanation.

Here are both, side by side.

One warning before you use that table. The Foundayo label says it outright: trials run under different conditions, so you cannot line up one drug's side effect rates against another's and call it a fair fight. We're showing you the numbers anyway, because you were going to look them up separately. Just read them as two stories, not a race.

Our math: the surprising part

• Nausea above placebo: CagriSema adds 42.4 points. Foundayo adds 25 points. In this cross-trial comparison, CagriSema shows about 1.7× more added nausea.
• Stopping above placebo: CagriSema adds 2.4 points. Foundayo adds 7 points. In this cross-trial comparison, Foundayo shows about 2.9× more added stopping.

Read that twice. The trial with far more nausea is the trial where more people stayed on treatment.

That is a pattern, not proof that one drug is easier to tolerate.

Why that happened — two reasons, one of them seen twice

Reason one, straight from Novo's trial design. CagriSema's trial let doctors keep a patient on a lower dose if that suited them better. Only 57.3% of patients were on the top dose at week 68. Foundayo's pivotal trials assigned people to fixed target doses. A trial that lets more people stay below the maximum can show fewer dropouts than one built around fixed targets.

Reason two, and this is what makes it worth watching. In ACHIEVE-3 — a separate diabetes trial with a different comparison drug — orforglipron again had a higher side-effect stopping rate: 9.7% versus 4.9% with oral semaglutide. The study was not designed to prove one drug was safer, so this is a signal, not a verdict.

So it may not be just a REDEFINE-versus-ATTAIN design quirk. Orforglipron does appear to be a drug some people walk away from.

What this actually means for you

Nausea, vomiting, diarrhea, or constipation can happen with either path. Foundayo's label says stomach side effects were more common while doses were being raised and generally fell over time.

But notice what can end treatment. It usually isn't one bad day. It's not having room to slow down.

So before you start, ask your prescriber one specific question: "If a dose increase is too rough, can I stay where I am for a while?" On Foundayo, the label requires at least 30 days at each step and says later increases are based on response and tolerability. You do not have to race to the top dose just because it exists.

Read more: Foundayo side effects, dose by dose

What does Foundayo actually cost, month by month?

Foundayo's published regular self-pay price climbs with your dose: $149 at the starting dose, $199 at 2.5 mg, $299 at 5.5 mg and 9 mg, and $349 at 14.5 mg and 17.2 mg. At the fastest label schedule, 12 months at the regular published prices total $3,738, with $1,295 spent before the first month at 17.2 mg. If Lilly's current $299 on-time top-dose offer were extended unchanged across the full 12-month example, the total would be $3,338, with $1,245 spent before 17.2 mg. That lower total is an illustration, not a promise: the current savings terms end December 31, 2026.

That last sentence is the one nobody tells you. Let's unpack it.

The label sets a five-month clock

Foundayo's label requires at least 30 days at each dose before you move up. Five steps stand between you and the top:

0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg

Five steps × 30 days = 150 days minimum. If every increase happens at the first allowed date, the earliest you can take your first 17.2 mg tablet is day 151. About five months.

Which reframes the famous number. That 11.1% is what happened at week 72 after participants climbed the ladder. It is not 72 weeks at the top dose. If you're expecting the full trial average by month three, the schedule itself says no.

A 12-month price scenario, month by month

The regular-price column uses Lilly's published prices on August 8, 2026. The offer column shows what the same 12 months would cost if the current $299 on-time top-dose offer continued unchanged. It does not currently run for a full future year: savings end December 31, 2026, the card is limited to 10 fills per calendar year, and Lilly can change the terms. Your prescriber may also hold you at a lower dose.

The 45-day rule is worth $400 if the current offer covers this full 12-month scenario

This is one of the most useful things on this page, so we put it in its own section.

At the top two doses, Foundayo's regular published price is $349 for a 30-day supply. Lilly's current offer drops that to $299 — but after the first eligible fill, you must complete each refill purchase within 45 days of receiving the prior fill. Let the window lapse and the $299 purchase offer does not apply.

In the 12-month fastest-escalation example above, the difference is $400 if the current offer remains available for every eligible top-dose fill. Set a calendar reminder the day your box arrives, but recheck the terms before each refill.

Three conditions to know: the offer applies to the 14.5 mg and 17.2 mg doses, the card can be used for no more than 10 prescription fills per calendar year, and the current terms say savings end December 31, 2026. That's not a scare tactic, it's a date on Lilly's page — check the live terms before you build a long budget around it.

What it really costs through a telehealth provider

Medication is one bill. The provider is another. Here's the honest all-in monthly number if you go through Ro, which lists Foundayo at Lilly's same current cash prices.

The annual membership is paid upfront for the year. Taxes and any extra fees are not included. Prices and program terms can change.

And here's something we'd rather you hear from us: if you already have a prescription in hand and do not need telehealth care, going through LillyDirect can cost less because there is no Ro membership fee. We don't get paid to tell you that.

What the membership buys is the part many people get stuck on. Somebody has to decide whether the medicine fits you and write the prescription. If you are trying to use insurance for a covered option, somebody may also need to file the prior authorization and respond when it is denied. Ro includes clinical care and support services with the membership. If you've got a doctor who'll write it and a path that already works, skip the membership. If you don't, that's what you're paying for.

One thing to correct about "11% in a year"

Several provider pages — including Ro's own Foundayo page — describe the result as losing about 11% "in a year."

The pivotal trial ran 72 weeks. That's about 16½ months, not 12. The 11.1% figure is real, but calling it a one-year result compresses the timeline. Plan for the longer clock.

You've seen the real number. Now see if you're a candidate. Ro's intake asks about your health history and your goals, then a licensed provider decides whether Foundayo is appropriate for you. Get started for $39, then as low as $74/month with an annual plan paid upfront — medication billed separately. → See if you qualify for Foundayo on Ro (sponsored affiliate link) Prices verified August 8, 2026. Ro carries multiple FDA-approved weight-loss paths, so the clinical decision is not limited to Foundayo.

What does CagriSema cost?

Nothing you can pay at a U.S. pharmacy today, because CagriSema is not approved or launched. It has no announced U.S. price, savings card, or patient assistance program. Any monthly figure you find online is an estimate, not a Novo Nordisk price.

We looked. Hard. There isn't one.

You may find price estimates on other sites. Those come from analysts or writers modeling what a combination drug might cost. They are not from Novo, they are not verified, and we're not going to repeat them as though they mean something.

One piece of real context, though: CagriSema would enter a fast-changing cash-price and coverage market if it is approved. That is another reason a 2027 price guess made in 2026 isn't worth much.

Related: Medicare GLP-1 Bridge tracker

If you want a pill, is Foundayo even the best pill?

Not on average. Counting everyone randomized, the Wegovy pill produced 13.6% average weight loss and Foundayo produced 11.1% — and both have current manufacturer cash programs starting at $149. But the Wegovy pill has to be taken in the morning on an empty stomach with no more than four ounces of water, followed by a 30-minute wait before food, drinks, or other oral medicines. Foundayo has no food, water, or time-of-day rule.

If you've decided you want a pill, this — not CagriSema — is your real decision.

Two caveats before you draw conclusions. OASIS 4 enrolled 307 people; ATTAIN-1 enrolled 3,127. A smaller trial gives a less precise estimate. And they ran for different lengths. These drugs were never compared head-to-head.

The head-to-head trial that keeps getting misquoted

You may have read that Foundayo's ingredient beat oral semaglutide in a head-to-head trial. That's true. It's also being used to mean something it doesn't.

The trial was ACHIEVE-3. Orforglipron did beat oral semaglutide on blood sugar and weight. But look at the details:

• The comparison doses were oral semaglutide 7 mg and 14 mg — the diabetes doses sold as Rybelsus, not the Wegovy pill's 25 mg weight-loss dose.
• The participants all had type 2 diabetes.
• It ran 52 weeks, and it was open-label — everybody knew what they were taking.

Some coverage has blurred that comparison into "Wegovy in a pill." It wasn't the 25 mg Wegovy pill studied for obesity.

No trial has compared Foundayo 17.2 mg with the Wegovy pill 25 mg. Anyone telling you Foundayo beat the Wegovy pill is stretching a real result past what it shows.

So why would you still pick Foundayo?

Because of that fourth row in the table.

The Wegovy pill routine is strict. Wake up. One pill. No more than four ounces of plain water. No coffee. No breakfast. No other oral medicine. Wait thirty minutes. Every morning.

Some people do that easily. A lot of people won't want to.

Foundayo has none of it. Different chemistry, no absorption enhancer, no special stomach conditions required. Take it with dinner. Take it at midnight. Take it with a full glass of water and a sandwich.

A drug you take correctly at 11.1% can beat a drug you take incorrectly at 13.6%. If your mornings are chaos — kids, shift work, a commute, coffee before consciousness — that difference can be worth more than two percentage points.

And why you might pick the Wegovy pill instead

Be honest with yourself here. If you're already a disciplined morning person, want the bigger average trial result, or specifically want semaglutide because Wegovy tablets have an FDA-approved indication for reducing major cardiovascular events in adults with established heart disease and obesity or overweight, the Wegovy pill can be the better answer.

Compare further: Wegovy pill vs Foundayo · Foundayo vs Zepbound · GLP-1 options without needles

Can you start Foundayo now and switch to CagriSema later?

Possibly, someday — but there is no FDA-approved Foundayo-to-CagriSema switching plan today, because CagriSema has no approved label. What we can tell you is that Foundayo's label does not recommend using it alongside another GLP-1 medicine, and CagriSema contains semaglutide, which is a GLP-1. A future switch would need a prescriber, not an online dose-conversion chart.

This is the fear underneath most "should I wait" searches, so let's handle it squarely.

What's actually known today:

• Foundayo's label says using it at the same time as another GLP-1 receptor agonist is not recommended.
• CagriSema contains semaglutide. That's a GLP-1 receptor agonist.
• CagriSema has no final label, so no approved washout time, starting dose, or conversion schedule exists.
• Starting Foundayo does not lock you into it forever. Treatment can change when your clinician has a reason to change it.

There is now a useful trial here, but it answers a different question. In the published ATTAIN-MAINTAIN study, 376 people who had first taken injectable tirzepatide or semaglutide were randomized to oral orforglipron or placebo. Orforglipron preserved more of their earlier weight loss than placebo over 52 weeks. That supports the idea that an injectable-to-orforglipron switch can be studied and managed. It does not create an approved Foundayo-to-CagriSema schedule, and its trial protocol should not be copied at home.

The part that should factor into your decision: switching can still feel like a step down while the new treatment is being adjusted.

A Drugs.com reviewer who said they had lost 105 pounds over 14 months on Zepbound reported switching to Foundayo in May 2026 and restarting at the 0.8 mg dose. They wrote that cravings came back "with a vengeance," reported regaining 6 pounds in 12 days, and rated the experience 1 out of 10.

That's one person's report, not a prediction and not a dosing rule. But it is a useful warning: the beginning of a new treatment may not feel like the top dose of the old one.

Questions worth saving for your prescriber:

1. If what I'm on is working, what problem would switching actually solve?
2. How long should I wait between the two medicines?
3. What dose would I start, and why?
4. What should I expect during the change?
5. Would my coverage change?

We're not going to publish a switching schedule. That's a decision for someone who knows your history and the final labels involved.

Who should not take Foundayo?

Foundayo is off the table if you or a family member has had medullary thyroid cancer, if you have MEN 2, or if you have had a serious allergic reaction to orforglipron or a Foundayo ingredient. The label also says it is not recommended with severe gastroparesis or severe liver impairment, during breastfeeding, or alongside another GLP-1 medicine. Stop it if pregnancy is recognized and call your prescriber.

The boxed warning, honestly

Foundayo carries a boxed warning about thyroid C-cell tumors. That's the FDA's most serious warning format, and it deserves a straight explanation rather than either panic or hand-waving.

Several major U.S. obesity GLP-1 labels carry a thyroid C-cell tumor warning because drugs with GLP-1 activity produced these tumors in rodents.

But the Foundayo label says something unusual, and it's worth knowing: orforglipron is not active in rats or mice, and it did not produce tumors in rodents. The warning remains because the human meaning of the rodent class finding has not been determined.

Does that mean the risk is zero? Nobody can say that. The label is explicit that the human relevance is unknown, which is exactly why the warning stays.

If you or a close relative has had medullary thyroid cancer, or you have MEN 2, this medicine is contraindicated. Full stop. Tell your prescriber.

Other warnings you should not bury

Foundayo's label also warns about acute pancreatitis, severe stomach problems, dehydration-related kidney injury, low blood sugar when used with insulin or an insulin-releasing drug, serious allergic reactions, diabetic eye disease complications, gallbladder disease, and aspiration during general anesthesia or deep sedation.

Tell the surgical or anesthesia team that you take Foundayo before a planned procedure. And get medical help for severe or lasting abdominal pain, signs of a serious allergy, or severe vomiting or diarrhea.

Drug interactions that actually change your dose

Straight from the label, in plain terms:

• Strong CYP3A4 inhibitors such as clarithromycin: the maximum Foundayo dose is 9 mg a day.
• A strong CYP3A4 inhibitor that also blocks OATP1B, such as ritonavir: avoid the combination.
• Strong CYP3A4 inducers such as carbamazepine: avoid. In testing, carbamazepine cut orforglipron exposure by 82%.
• Moderate CYP3A4 inducers: your clinician may need to monitor whether Foundayo is working and adjust the dose within the label.
• Simvastatin: do not take more than 20 mg a day with Foundayo.
• Other oral medicines: Foundayo slows stomach emptying and can change how quickly other pills are absorbed. Bring your full medicine list.

The birth control window most pages skip

This one is genuinely important and we haven't seen it spelled out anywhere else.

Foundayo's label says people using oral hormonal birth control should switch to a non-oral method, or add a barrier method, for 30 days after starting — and for 30 days after every dose increase.

Count the increases. One start plus five possible dose increases equals six separate 30-day windows.

Now put that against the dosing schedule. If you move up at the label's minimum pace of 30 days per step, those windows sit back to back with no gap between them. That works out to roughly 180 days — about six months — of continuously needing non-oral or backup contraception while you climb to the top dose.

That's not a scare. It's a planning fact. And if you rely on the pill for birth control, it's a completely legitimate reason to prefer a different treatment path.

Missing doses works differently than with a shot

If you miss one dose, take it as soon as possible and do not double the next one.

If you miss seven or more doses in a row, the label says to restart dose escalation at a lower dose to reduce stomach side effects. It does not give one universal restart dose in that sentence, so ask your prescriber which lower dose fits you.

That's a real disadvantage of a daily pill that a weekly injection doesn't have in the same way. If you travel a lot, or your routine falls apart regularly, factor it in honestly.

If any of this rules you out, don't just close the tab. Foundayo vs Zepbound covers the injectable path, and Find My GLP-1 Path will route you based on your actual situation.

What real Foundayo users are saying

As of August 8, 2026, Drugs.com lists 29 Foundayo reviews with an average rating of 6.9 out of 10 — 52% of reviewers reported a positive experience and 14% reported a negative one. That's a small, self-selected sample from a medicine that has only been on the U.S. market for four months, and it is not clinical evidence.

CagriSema has no legitimate postmarket patient ratings yet for a simple reason: it has not been approved or prescribed as a marketed medicine. A page calling itself a "CagriSema review" may be describing trial data or an unapproved product, not the finished medicine you could pick up from a pharmacy.

Foundayo does have real user reports. Here are three, with dates and ratings, chosen because each one tells you something different.

"No needles is so much better." — Drugs.com reviewer, June 18, 2026, rated 7/10

This person said they had lost about 35 pounds on the Wegovy pen, then tried the Wegovy pill and found the rules annoying. They reported that Foundayo's side effects were milder for them but included more anxiety, and that weight loss became more noticeable after the first dose level.

"I don't like needles, so this option is fantastic." — Drugs.com reviewer, May 26, 2026, rated 10/10

They described a few days of nausea at the start, then feeling fine, and specifically praised not having to take it on an empty stomach or limit their water.

"So many cravings are back with a vengeance." — Drugs.com reviewer, May 27, 2026, rated 1/10

This is the one we most want you to read. They said they had lost 105 pounds over 14 months on Zepbound, switched to Foundayo, restarted at 0.8 mg, and regained 6 pounds in 12 days.

These are individual reports. They are not typical results, they are not clinical evidence, and they can't tell you what will happen to you.

The pattern the star rating does not show

We read the 25 reviews visible on the first page of the Drugs.com listing on August 8, 2026. The pattern was messier than a clean sales story.

Some low ratings came from people who were still on 0.8 mg or 2.5 mg and felt little appetite control. That lines up with the label's long climb: the earliest top dose is day 151.

But early dosing did not explain every bad review. Other low or middle ratings described lasting stomach problems, anxiety, or weak results after longer use. The reviews do not support a simple "just wait and everyone gets better" promise.

The honest read is narrower: do not judge the full 17.2 mg trial result by your first weeks on 0.8 mg — but do not dismiss a problem just because you are early, either. Talk to the prescriber managing the dose.

Twenty-five self-selected reviews is not a study. People post when they're thrilled or furious, rarely when things are ordinary. Treat this as a pattern worth knowing, not proof.

How to actually get Foundayo — and the insurance catch

You need a prescription. Once you have one, you can fill Foundayo through LillyDirect for home delivery, at a retail pharmacy, or through a telehealth provider that handles the visit and prescription. If you have Medicare Part D, the temporary GLP-1 Bridge may cover Foundayo with a $50 copay through December 31, 2027 — but only for eligible beneficiaries after the program's prior authorization process.

The Medicare catch

The phrase "about $50 on Medicare" is too loose by itself.

The Bridge is a temporary CMS program from July 1, 2026, through December 31, 2027. It is for eligible Medicare Part D beneficiaries, and the $50 is a program copay, not a promise for every person with Part D. The prescriber must use the Bridge prior authorization process after a pharmacy claim is denied. The form checks BMI and specific health conditions, and some diagnoses must be handled through the person's Part D plan instead.

So the useful question is not "Do I have Medicare?" It is "Do I meet the Bridge rules, and will my prescriber submit the prior authorization?"

The Ro insurance-checker catch nobody mentions

Here's something we checked ourselves on August 8, 2026, and it's worth knowing before you spend an afternoon on it.

Ro runs a free GLP-1 Insurance Coverage Checker. It's genuinely useful — their team calls your insurance company for you and emails you a personalized report. But Ro's own page says the tool currently checks the Ozempic pen, Wegovy pen, and Zepbound pen. It does not currently check the Foundayo pill, Wegovy pill, or Zepbound KwikPen.

So if someone tells you to use Ro's free checker for Foundayo, that is not currently what the tool does. Ro lists Foundayo as a cash-pay option. For Foundayo coverage specifically, call your plan, ask your pharmacy to run the claim, or ask your prescriber's office or telehealth care team to check benefits and handle any prior authorization.

And if you're open to a pen instead of a pill, the free checker does work for those three pens — and Ro currently says new accounts receive a $50 credit with the free report.

If insurance is the deciding factor, start there instead of with the drug. Ro will call your plan, then email you a report showing coverage for the Ozempic pen, Wegovy pen, and Zepbound pen. It's free, and new accounts currently get a $50 credit. → Check your coverage free on Ro (sponsored affiliate link) Ro cannot currently check coverage for the Foundayo pill, Wegovy pill, or Zepbound KwikPen. Verified August 8, 2026.

More on coverage: Medicare GLP-1 Bridge tracker · GLP-1 insurance appeal letter template

How we compared CagriSema and Foundayo

We built this page from the FDA-approved Foundayo label, the published ATTAIN-1, ATTAIN-2, ATTAIN-MAINTAIN, and REDEFINE 1 results, the direct REDEFINE 4 headline results, and current pricing pages from Lilly and Ro. We did the arithmetic ourselves and showed our work. We did not treat two separate trials as if they were a head-to-head study.

Provider-stated vs primary-source verified

What we actually verified — August 8, 2026

• ✅ Foundayo's FDA approval date, indication, dosing ladder, warnings, contraindications, missed-dose rule, and drug interactions — read directly from the current prescribing information
• ✅ The full capsule-to-tablet crosswalk — stated in the published ATTAIN-MAINTAIN paper and checked against ATTAIN-1, ATTAIN-2, and the FDA label
• ✅ CagriSema's U.S. status, December 18, 2025 filing, REDEFINE 1 result, REDEFINE 4 result, and expected Q4 2026 decision window — from Novo's releases and investor materials
• ✅ Foundayo's current price at every dose, the 45-day refill condition, the 10-fill annual limit, and the December 31, 2026 savings end date — from Lilly's published terms
• ✅ Ro's membership pricing and Foundayo cash pricing
• ✅ Ro's statement that its free insurance checker cannot currently check Foundayo
• ✅ CMS Bridge dates, $50 copay, and prior authorization requirement
• ✅ The Drugs.com Foundayo review count, average rating, and every review quoted here

What we could not verify, and left out

• ❌ A CagriSema price. Novo has not announced one.
• ❌ A CagriSema launch date. An expected decision window is not a launch date.
• ❌ Whether CagriSema will be approved. Nobody outside the FDA can promise this.
• ❌ A separate CagriSema diarrhea rate from the main REDEFINE 1 publication. We left it blank rather than estimating it.
• ❌ An approved Foundayo-to-CagriSema switching schedule. No final CagriSema label exists.

What we deliberately did not do

We didn't blend diabetes-trial results with obesity-trial results. We didn't present CagriSema's trial safety data as though it were an approved label. We didn't confuse medication price with membership price. We didn't treat user reviews as evidence of how well the drug works. And we didn't turn "decision expected" into "available."

Sources we relied on, in order of weight

1. FDA approval documents and current prescribing information
2. Peer-reviewed trial publications
3. Manufacturer regulatory filings, trial announcements, and published pricing terms
4. CMS program materials
5. Current provider pricing and policy pages
6. Drugs.com user reviews — for individual experience only, never for efficacy or safety claims

Change log

Frequently asked questions

Is CagriSema better than Foundayo?

In separate main trials, CagriSema produced about twice Foundayo's placebo-adjusted average weight loss. But they have never been compared directly, and only Foundayo is FDA-approved and available. If your question is which one you can start now, the answer is Foundayo. If your question is which available medicine produced the biggest average loss, the answer is Zepbound.

Is CagriSema FDA-approved?

No. Novo Nordisk filed its U.S. application on December 18, 2025 and says it expects an FDA decision in Q4 2026. Approval is not guaranteed.

When will CagriSema be available?

No launch date has been announced. A late-2026 FDA action would still need to be followed by an approval, final label, price, launch, distribution, prescriber access, and insurance decisions.

Which one produced more weight loss in trials?

CagriSema: 20.4% counting everyone randomized and 22.7% under the stay-on-treatment analysis. Foundayo: 11.1% and 12.4%. These came from different trials with different lengths, not a direct comparison.

Were CagriSema and Foundayo ever tested head-to-head?

No. The figures come from REDEFINE 1 and ATTAIN-1, which were separate placebo-controlled studies run by different companies.

Which one has worse side effects?

The separate trials cannot settle that. CagriSema's trial reported more nausea — 55% versus 35% at Foundayo's top dose — but Foundayo's pooled label trials show more people stopping because of side effects — 10% at the top dose versus 5.9% with CagriSema. Different designs may explain part of that gap.

Which one is cheaper?

Only Foundayo has a real U.S. price today. Current published regular self-pay prices run from $149 to $349 for a 30-day supply by dose. Eligible people with commercial coverage may pay as little as $25. CagriSema has no announced U.S. price.

Why do some sites say 36 mg and others say 17.2 mg?

The studies used an investigational capsule formulation. The approved product uses tablet equivalents. The published crosswalk maps 36 mg capsule to 17.2 mg tablet, along with the five lower dose pairs shown above.

Does insurance cover Foundayo?

It depends on your plan. Commercial coverage may require prior authorization. Eligible Medicare Part D beneficiaries may use the temporary GLP-1 Bridge for a $50 copay after its prior authorization process. Ro's standalone free coverage checker does not currently check Foundayo.

How long until I'm on the full Foundayo dose?

At least 150 days before the first 17.2 mg dose if every increase happens at the first allowed date. The label requires at least 30 days at each of five lower doses, and later increases depend on response and tolerability.

Can you take Foundayo and CagriSema together?

Do not assume so. Foundayo's label does not recommend using it with another GLP-1 medicine, and CagriSema contains semaglutide, which is a GLP-1 receptor agonist.

Can I start Foundayo now and switch to CagriSema later?

Possibly, with a prescriber's guidance, if CagriSema is approved. But no approved CagriSema switch plan exists today. Do not use an online washout or dose-conversion schedule.

Can I buy CagriSema now?

No FDA-approved CagriSema is available. The FDA says cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition.

Is Foundayo the same thing as Zepbound in a pill?

No. Zepbound is tirzepatide, a peptide that works at GIP and GLP-1 receptors. Foundayo is orforglipron, a small molecule that works at the GLP-1 receptor. Same company, different drugs.

Does Foundayo cause hair loss?

Hair loss is listed as a common adverse reaction. It occurred in 5% at the top dose in pooled trials and more often in women than men — 7% versus 0.9%. The label says it was associated with weight reduction.

Will CagriSema be a pill?

No. The product under FDA review is a once-weekly injection combining cagrilintide and semaglutide.

The bottom line

If you and your prescriber decide it is time to start, start something you can actually get. Foundayo is approved, it is a pill with no food, water, or time-of-day rule, and its current manufacturer self-pay price starts at $149.

If the biggest possible average number is what you're after, that's Zepbound — and it is available now too.

And if you're waiting for CagriSema because you believe it is stronger than everything else out there, please look at the direct trial one more time. Zepbound already beat it in the same people. Wegovy 7.2 mg also came close in a separate all-randomized trial result.

Waiting used to be the smart move. In 2026, for most people, it's mostly just waiting.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Related guides

• Foundayo vs Zepbound: pill vs shot
• Wegovy pill vs Foundayo pill
• CagriSema FDA approval status
• What is CagriSema?
• Foundayo side effects, dose by dose
• Foundayo cost without insurance
• Best Foundayo providers
• Medicare GLP-1 Bridge tracker
• GLP-1 options without needles
• Does Ro have a membership fee?

Sources

1. FDA. Foundayo approval announcement, April 1, 2026.
2. Eli Lilly. Foundayo prescribing information, revised July 2026.
3. Wharton S, Aronne LJ, et al. Orforglipron for obesity treatment, ATTAIN-1. New England Journal of Medicine. 2025;393(18):1796–1806.
4. Horn DB, et al. Orforglipron for obesity in people with type 2 diabetes, ATTAIN-2. The Lancet.
5. ATTAIN-MAINTAIN. Nature Medicine. 2026.
6. Novo Nordisk. CagriSema FDA filing announcement, December 18, 2025.
7. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity, REDEFINE 1. New England Journal of Medicine. 2025.
8. Novo Nordisk. REDEFINE 4 headline results, February 23, 2026.
9. Novo Nordisk. Q2 2026 investor presentation, August 2026.
10. FDA. Wegovy 7.2 mg approval announcement, March 19, 2026.
11. Novo Nordisk. Current Wegovy prescribing information.
12. Eli Lilly. Current Zepbound prescribing information.
13. Novo Nordisk. Current Saxenda prescribing information.
14. FDA. Concerns with unapproved GLP-1 drugs used for weight loss.
15. Eli Lilly. Foundayo coverage, self-pay prices, and savings terms.
16. CMS. Medicare GLP-1 Bridge program.
17. CMS. Medicare GLP-1 Bridge prior authorization form.
18. Ro. Foundayo and Ro Body pricing.
19. Ro. GLP-1 Insurance Coverage Checker.
20. Rosenstock J, et al. Orforglipron compared with oral semaglutide in adults with type 2 diabetes, ACHIEVE-3. The Lancet. 2026.
21. Drugs.com. Foundayo user reviews, accessed August 8, 2026.

Medical disclaimer: This page is for information only. It is not medical advice, it is not a diagnosis, and it cannot tell you whether any medicine is right for you. Talk to a licensed clinician before starting, stopping, or switching any medication. The RX Index is not affiliated with Eli Lilly, Novo Nordisk, or any pharmaceutical manufacturer.